Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's

This page shows the latest Alzheimer's news and features for those working in and with pharma, biotech and healthcare.

GW Pharma's cannabis-based medicine to be tested in dementia

GW Pharma's cannabis-based medicine to be tested in dementia

Trial will be funded by Alzheimer’s Research UK. Alzheimer’s Research UK is to sponsor a clinical trial of GW Pharmaceuticals’ Sativex to treat agitation and aggression in people with ... Now the oral spray will now undergo testing to examine

Latest news

  • Alector kicks off next wave of biotech IPOs Alector kicks off next wave of biotech IPOs

    overcome disappointments seen in neurology, most especially in Alzheimer’s disease. ... Its initial focus is on frontotemporal dementia (AL001 entering phase 1 trials in September) and Alzheimer’s disease, AL002 also entering phase 1 in December.

  • J&J bolsters gene therapy unit with $100m MeiraGTx deal J&J bolsters gene therapy unit with $100m MeiraGTx deal

    J&J’s earlier forays into this area include a collaboration with the University of Pennsylvania on an Alzheimer’s programme, announced in early 2018. ... In Europe, the first approved gene therapy – UniQure’s Glybera – was launched way back in

  • Ocrevus helps Roche shrug off biosimilars in 2018 Ocrevus helps Roche shrug off biosimilars in 2018

    Good news after Alzheimer's failure. Roche saw a decline in its European sales last year as biosimilars started to bite its blockbuster biologic drugs, but strong growth for new products ... The buoyant performance will help numb the pain of Roche’s

  • Another amyloid bust as Roche pulls crenezumab trials Another amyloid bust as Roche pulls crenezumab trials

    Undermines amyloid hypothesis hopes. including Biogen candidate. Roche has halted a pair of phase 3 trials for its amyloid-targeting antibody crenezumab in Alzheimer’s disease (AD) after an interim look ... It’s not the end of the story for the drug

  • Researchers reverse Alzheimer’s memory loss in mice Researchers reverse Alzheimers memory loss in mice

    The Buffalo researchers believe their work in the developing science of epigenetics will yield answers in the elusive search for new Alzheimer's therapies. ... Meanwhile, the next big hope in the pharma industry’s late stage pipeline for Alzheimer’s

More from news
Approximately 91 fully matching, plus 376 partially matching documents found.

Latest Intelligence

  • Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available? Alzheimers disease – is Europe prepared if a breakthrough treatment becomes available?

    Currently, there is no Alzheimer’s disease- modifying treatment available but there are several therapies in development. ... In France, 389, 000 people might develop Alzheimer’s dementia while waiting for evaluation and treatment.

  • Key considerations for disease- modifying Parkinson’s disease trials Key considerations for disease- modifying Parkinson’s disease trials

    ‘Lessons learnt from Alzheimer’s trials could help in Parkinson’s drug development’. ... The design of such neuroprotective studies may benefit from the lessons learned in studies in the most common neurodegenerative disease, Alzheimer’s.

  • Tackling a formidable foe Tackling a formidable foe

    MAVENCLAD’S short-course oral therapy profile is a bonus to a condition freighted with psychological drag-weights. ... s or Alzheimer’s.

  • What can pharma learn from the charity sector? What can pharma learn from the charity sector?

    the charity sector (or third sector, as it’s also known) to better support its patients. ... Dr Doug Brown, Chief Policy and Research Officer at Alzheimer’s Society, explains how co-creation is an essential part of its research process:.

  • Deal Watch January 2018

    Under this transaction Takeda gains options to three Denali programmes for neurodegenerative disorders: the ATV: BACE1/Tau and ATV: TREM2 programmes, which are both at preclinical stage for Alzheimer's disease, ... Collaboration, licence. 830. Molecular

More from intelligence
Approximately 2 fully matching, plus 39 partially matching documents found.

Latest appointments

  • Cognite strengthens team with two new additions Cognite strengthens team with two new additions

    She has demonstrated real drive and talent across a wide range of disease areas including oncology, MS, diabetes and Alzheimer’s, making her ideally suited to help build successful breakthrough science

  • Metrion Biosciences establishes scientific advisory board Metrion Biosciences establishes scientific advisory board

    The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011. ... Alzheimer's disease.

  • UK Dementia Research Institute names director UK Dementia Research Institute names director

    In his new role, Prof De Strooper will work with the institute's founding partners - the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK - to develop new therapeutics

More from appointments
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest from PMHub

  • Random42 attending Biotech Showcase in San Francisco

    Alzheimer’s Disease. Cell and Gene Therapy. Immuno-Oncology. NASH (Nonalcoholic steatohepatitis). Rare and Orphan Diseases. ... Please contact us at info@random42.com to arrange a meeting. For more information on Random42’s capabilities please see

  • The dark side of direct-to-consumer genetic tests

    Who can blame them? If an email landed in your inbox that appeared to indicate you had an increased risk of cancer, Parkinson’s disease, Alzheimer’s disease, or any other

  • Attigo (part of the Mednet Group)

    Alzheimer’s Research UK. Alzheimer’s Society. Basic Needs. Biogen. Butterfly Scheme. Cardiomyopathy UK. ... Mednet Group's white paper with a focus on navigating the world of work is available online in aid of World Mental Health Day 2018.

  • Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies

    the US suffer from Alzheimer’s disease, and  795, 000  Americans suffer from strokes annually. ... It’s a little bit like it was in the old days of buying IBM computers,” he says.

  • Synergy Vision

    Alzheimer's and Brain Awareness Month. ... June 2017 is Alzheimer’s and Brain Awareness Month, which aims to raise awareness about Alzheimer’s disease (AD) and other types of dementia.

More from PMHub
Approximately 3 fully matching, plus 16 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics